Rifaximin-α for ALD: phase II results

In a randomized, double-blind, single-centre, phase II trial, investigators assessed the safety and efficacy of oral rifaximin-α compared with placebo in patients with alcohol-related liver disease (ALD). Patients with biopsy-proven ALD (n = 136) were randomly allocated (1:1) to rifaximin-α (550 mg) twice daily or placebo for 18 months. In the per-protocol analysis, 26% of patients in the treatment group and 28% of the placebo group had a decrease in fibrosis stage after 18 months (OR 1.10 (95% CI 0.45–2.68); P = 0.83). However, rifaximin-α significantly reduced progression of fibrosis stage compared with placebo.

留言 (0)

沒有登入
gif